Table 2: Prognostic scoring systems for patients with refractory/ relapsed AML: GOELAMS score [20].
|
Factor |
Points |
|
|
CR1 duration |
|
|
|
|
≥12monats |
0 |
|
|
≤12monats (refractory/early relapse) |
1 |
|
FLT3-ITD status |
|
|
|
|
Negative |
0 |
|
|
Positive |
1 |
|
Cytogenetics |
|
|
|
|
Favorable/intermediate |
0 |
|
|
High risk |
1 |
Prognostic groups: good (0 points; OS 58%, event-free survival [EFS] 45% at 2 years); intermediate (1 point; OS 37%, EFS 31% at 2 years); poor (2-3 points; OS 12%, EFS 12% at 2 years).